Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.
The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.
Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.
